FDA Accepts Inhibrx BLA for Ozekibart in Rare Bone Cancer Treatment

Key Facts

1The U.S. FDA accepted the Biologics License Application for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.

In a move reflecting the critical regulatory path for biotech firms targeting rare diseases, Inhibrx Biosciences announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart. The application seeks approval for the drug, also designated as INBRX-109, to treat unresectable or metastatic conventional chondrosarcoma. The FDA has established a PDUFA goal date of April 14, 2027, to complete its review of the treatment.

This regulatory milestone arrives as the healthcare sector intensifies its focus on specialized oncology treatments for rare bone cancers that currently have no approved therapies. Per market data, INBX shares closed at $92.20 on June 12, 2026, after trading between a low of $88.63 and a high of $95.26 during the session. Analysts note that while the acceptance is bullish, the long lead time to the 2027 decision date remains a key factor for long-term valuation models.

Looking ahead, investors will monitor for interim clinical data updates that could serve as catalysts before the 2027 deadline. From a macro perspective, the upcoming U.S. CPI inflation data on June 10, 2026, will be a significant event for interest-rate-sensitive biotech stocks. Based on recent trading, the June 12, 2026, high of $95.26 serves as a primary resistance level for INBX shares in the near term.